FierceBiotech1h
Aviceda raises $207M series C to take geographic atrophy drug through phase 3
Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...
FierceBiotech2h
Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
FierceBiotech2h
Candid's T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M
Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...
FierceBiotech4h
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
FierceBiotech3h
Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
FierceBiotech2h
CytomX lays off 40% of staff, questions future of Amgen-partnered T-cell engager
CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.
FierceBiotech19h
FDA draft guidance recommends tissue biopsies only be required in trials if necessary and low risk
Because of the risks biopsies can pose to patients, the FDA recommends only requiring them as part of trial participation if ...